Biotechnology market research reports by DelveInsight

• Cell And Gene Therapy For Multiple Myeloma – Market Insight, Epidemiology, and Market Forecast – 2034

  Jun 01, 2024  |  Published by: DelveInsight  |  USD 7,950

  Cell And Gene Therapy For Multiple Myeloma – Market Insight, Epidemiology, and Market Forecast – 2034 DelveInsight's ""Cell And Gene Therapy For Multiple Myeloma – Market Insights, Epidemiology, and Market Forecast – 2034"" report delivers an in-depth understanding of the Cell And Gene Therapy For M ... Read More

• Allogeneic T-cell therapy for autoimmune diseases – Market Insight, Epidemiology, and Market Forecast – 2034

  Jun 01, 2024  |  Published by: DelveInsight  |  USD 7,950

  Allogeneic T-cell therapy for autoimmune diseases – Market Insight, Epidemiology, and Market Forecast – 2034 DelveInsight's ""Allogeneic T-cell therapy for autoimmune diseases – Market Insights, Epidemiology, and Market Forecast – 2034"" report delivers an in-depth understanding of the Allogeneic T- ... Read More

• Antibody-Mediated Graft Rejection – Market Insight, Epidemiology, and Market Forecast – 2034

  Jun 01, 2024  |  Published by: DelveInsight  |  USD 7,950

  Antibody-Mediated Graft Rejection – Market Insight, Epidemiology, and Market Forecast – 2034 DelveInsight's ""Antibody-Mediated Graft Rejection – Market Insights, Epidemiology, and Market Forecast – 2034"" report delivers an in-depth understanding of the Antibody-Mediated Graft Rejection, historical ... Read More

• Gene Therapies for Cardiomyopathies – Market Insight, Epidemiology, and Market Forecast – 2034

  Jun 01, 2024  |  Published by: DelveInsight  |  USD 7,950

  Gene Therapies for Cardiomyopathies – Market Insight, Epidemiology, and Market Forecast – 2034 DelveInsight's ""Gene Therapies for Cardiomyopathies – Market Insights, Epidemiology, and Market Forecast – 2034"" report delivers an in-depth understanding of the Gene Therapies for Cardiomyopathies, hist ... Read More

• Nucleic Acid and Gene Therapies in Neuromuscular Disorders – Market Insight, Epidemiology, and Market Forecast – 2034

  Jun 01, 2024  |  Published by: DelveInsight  |  USD 7,950

  Nucleic Acid and Gene Therapies in Neuromuscular Disorders – Market Insight, Epidemiology, and Market Forecast – 2034 DelveInsight's ""Nucleic Acid and Gene Therapies in Neuromuscular Disorders – Market Insights, Epidemiology, and Market Forecast – 2034"" report delivers an in-depth understanding of ... Read More

• Sickle Cell Disease - Epidemiology Forecast - 2034

  Jun 01, 2024  |  Published by: DelveInsight  |  USD 3,950

  Sickle Cell Disease - Epidemiology Forecast - 2034 Key Highlights In 2023, the United States accounted for the highest number of total prevalent cases of SCD trait with approximately 54% cases found in the 6MM. The prevalence of SCD cases was found to be high and rapidly increasing in the 6MM countr ... Read More

• 20s Proteasome Inhibitor - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  20s Proteasome Inhibitor - Pipeline Insight, 2024 “20s Proteasome Inhibitor - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 20s Proteasome Inhibitor development. The report provides d ... Read More

• CAR T-cell Therapy - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 3,000

  CAR T-cell Therapy - Pipeline Insight, 2024 DelveInsight’s, “CAR T-cell Therapy - Pipeline Insight, 2024” report provides comprehensive insights about 300+ companies and 300+ pipeline drugs in CAR T-cell Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclin ... Read More

• Neo Antigen T-cell Therapy - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Neo Antigen T-cell Therapy - Pipeline Insight, 2024 Neo Antigen T-cell Therapy Overview ""Neo Antigen T-cell Therapy Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Neo Antigen T-cell Therapy mark ... Read More

• CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2024 DelveInsight’s, “CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape. It cover ... Read More

• Olpasiran Market Size, Forecast, and Emerging Insight − 2032

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 3,250

  Olpasiran Market Size, Forecast, and Emerging Insight − 2032 “Olpasiran Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about olpasiran for myocardial infarction in the seven major markets. A detailed picture of the olpasiran for myocardial infarction in th ... Read More

• Acute Lymphoblastic Leukemia (ALL) - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Acute Lymphoblastic Leukemia (ALL) - Pipeline Insight, 2024 Acute Lymphoblastic Leukemia (ALL) Overview ""Acute Lymphoblastic Leukemia (ALL) Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute L ... Read More

• Anti-CD80 Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti-CD80 Antibody - Pipeline Insight, 2024 “Anti-CD80 Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD80 Antibody development. The report provides detailed coverage o ... Read More

• Antibody-Mediated Graft Rejection - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Antibody-Mediated Graft Rejection - Pipeline Insight, 2024 Antibody-Mediated Graft Rejection Overview ""Antibody-Mediated Graft Rejection Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Antibody-M ... Read More

• Anti-CD37 Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti-CD37 Antibody - Pipeline Insight, 2024 “Anti-CD37 Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD37 Antibody development. The report provides detailed coverage o ... Read More

• Anti-Dickkopf-1 (Dkk-1) Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti-Dickkopf-1 (Dkk-1) Antibody - Pipeline Insight, 2024 “Anti-Dickkopf-1 (Dkk-1) Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-Dickkopf-1 (Dkk-1) Antibody developmen ... Read More

• Anti-CD152 Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti-CD152 Antibody - Pipeline Insight, 2024 “Anti-CD152 Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD152 Antibody development. The report provides detailed coverag ... Read More

• Myasthenia Gravis - Market Insight, Epidemiology And Market Forecast - 2034

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 7,950

  Myasthenia Gravis - Market Insight, Epidemiology And Market Forecast - 2034 Key Highlights The main treatment options for ALL include chemotherapy, targeted therapy, immunotherapy, surgery, radiation therapy, and stem cell transplant. In the last few years, immunotherapy has undergone a new phase of ... Read More

• Alpha-1 Protease Inhibitor Deficiency - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Alpha-1 Protease Inhibitor Deficiency - Pipeline Insight, 2024 Alpha-1 Protease Inhibitor Deficiency Overview ""Alpha-1 Protease Inhibitor Deficiency Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across th ... Read More

• G-Protein Coupled Receptor (GPCR) Agonist - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  G-Protein Coupled Receptor (GPCR) Agonist - Pipeline Insight, 2024 “G-Protein Coupled Receptor (GPCR) Agonist - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across G-Protein Coupled Recepto ... Read More

• Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) - Pipeline Insight, 2024 Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) Overview ""Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT) Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present ... Read More

• Allogenic Cell Therapies - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Allogenic Cell Therapies - Pipeline Insight, 2024 Allogenic Cell Therapies Overview ""Allogenic Cell Therapies Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Allogenic Cell Therapies market. A de ... Read More

• Anti GM-CSF Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti GM-CSF Antibody - Pipeline Insight, 2024 “Anti GM-CSF Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti GM-CSF Antibody development. The report provides detailed cove ... Read More

• Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2024 “Anti-Mucin 1 (MUC1) Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-Mucin 1 (MUC1) Antibody development. The repor ... Read More

• Anti-CD19 Antibody - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Anti-CD19 Antibody - Pipeline Insight, 2024 “Anti-CD19 Antibody - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Anti-CD19 Antibody development. The report provides detailed coverage o ... Read More

< prev 1 2 3 4 5 6 7 8 9 next >